Regarding degree of innovation, we did not observe a consistent trend with first-in-indication ranging from 2 to 11% and first-in-class from 28 to 54% over time; the share of next-in-class medication also did not exhibit a clear trend ranging from 46 to 60% in the past 4 years.
← all excerpts
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.
1
—
—